Replies to post #16 on Aerie Pharmaceuticals Inc. (AERI)

[chaostrader]

Good chance AERI its done.
Phase 3 trial evaluating its lead product candidate, Rhopressa (eye drops), for lowering intraocular pressure in patients with glaucoma or ocular hypertension failed to achieve its primary efficacy endpoint of non-inferiority.